The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study

Abstract Background Treatment goals for patients with systemic lupus erythematosus (SLE) include minimising disease activity and reducing the risk of flares. Although belimumab is effective at reducing disease activity and risk of severe flares, it was previously unknown what the clinical effects we...

Full description

Bibliographic Details
Main Authors: Sang-Cheol Bae, Damon L. Bass, Myron Chu, Paula Curtis, Richard Dimelow, Laurence Harvey, Beulah Ji, Regina Kurrasch, Saima Muzaffar, Raj Punwaney, David A. Roth, Yeong-Wook Song, Wendy Xie, Fengchun Zhang
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Arthritis Research & Therapy
Subjects:
Systemic lupus erythematosus and autoimmunity
B cells
Lymphocytes
Biological therapies
Biomarkers
Online Access:https://doi.org/10.1186/s13075-022-02723-y

Internet

https://doi.org/10.1186/s13075-022-02723-y

Similar Items